B Fischler1,2, E Ellis3,4, H Johansson3,4, J F Svensson5,6, M Almström5,6, N Van Hul7, M Rudling8, B Angelin8, G Nowak3,4. 1. Division of Paediatrics, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, Stockholm, Sweden. 2. Department of Pediatrics, Karolinska University Hospital, Stockholm, Sweden. 3. From the, Division of Transplantation Surgery, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, Stockholm, Sweden. 4. Department of Transplantation, Karolinska University Hospital, Stockholm, Sweden. 5. Division of Pediatric Surgery, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden. 6. Department of Pediatric Surgery, Karolinska University Hospital, Stockholm, Sweden. 7. Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden. 8. Unit for Metabolism, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Abstract
BACKGROUND: Fibroblast growth factor 19 (FGF19) is produced in the small intestine and is involved in suppression of hepatic bile acid (BA) synthesis. FGF19 is also expressed in the liver and serum levels are elevated in adults with cholestatic liver disease. This may reflect a rescue mechanism to dampen liver injury caused by increased intrahepatic BAs. OBJECTIVES: To examine circulating FGF19 at early stages of biliary atresia and at short-term follow-up post-Kasai portoenterostomy (KPE) in relation to noncholestatic infants. The relationship between FGF19, BAs and markers for BA synthesis and hepatic gene expression of factors involved in BA metabolism were also evaluated. METHODS: Liver tissue, portal and peripheral blood samples were obtained from fifteen patients at KPE; additional blood was collected 4-6 months after surgery. Two control groups were included; to examine possible changes related to surgery and to compare FGF19 in biliary atresia to noncholestatic infants. RESULTS: Circulating FGF19 levels correlated to its hepatic gene expression at time of KPE in biliary atresia and levels were elevated compared to noncholestatic infants. At follow-up, FGF19 levels were markedly reduced, and the decline coincided with reductions in bilirubin and conjugated chenodeoxycholic acid and with increased levels of the BA synthesis marker C4. CONCLUSION: Elevated circulating FGF19 in biliary atresia is of hepatic origin and reduced following KPE. Changes in serum FGF19 may reflect the level of restoration of the enterohepatic circulation, and this warrants further long-term studies on the role of FGF19 in the cholestatic liver.
BACKGROUND:Fibroblast growth factor 19 (FGF19) is produced in the small intestine and is involved in suppression of hepatic bile acid (BA) synthesis. FGF19 is also expressed in the liver and serum levels are elevated in adults with cholestatic liver disease. This may reflect a rescue mechanism to dampen liver injury caused by increased intrahepatic BAs. OBJECTIVES: To examine circulating FGF19 at early stages of biliary atresia and at short-term follow-up post-Kasai portoenterostomy (KPE) in relation to noncholestatic infants. The relationship between FGF19, BAs and markers for BA synthesis and hepatic gene expression of factors involved in BA metabolism were also evaluated. METHODS: Liver tissue, portal and peripheral blood samples were obtained from fifteen patients at KPE; additional blood was collected 4-6 months after surgery. Two control groups were included; to examine possible changes related to surgery and to compare FGF19 in biliary atresia to noncholestatic infants. RESULTS: Circulating FGF19 levels correlated to its hepatic gene expression at time of KPE in biliary atresia and levels were elevated compared to noncholestatic infants. At follow-up, FGF19 levels were markedly reduced, and the decline coincided with reductions in bilirubin and conjugated chenodeoxycholic acid and with increased levels of the BA synthesis marker C4. CONCLUSION: Elevated circulating FGF19 in biliary atresia is of hepatic origin and reduced following KPE. Changes in serum FGF19 may reflect the level of restoration of the enterohepatic circulation, and this warrants further long-term studies on the role of FGF19 in the cholestatic liver.
Authors: Nicole Lind Henriksen; Svend Høime Hansen; Matthew Domenic Lycas; Xiaoyu Pan; Thomas Eriksen; Lars Søndergaard Johansen; Richard R Sprenger; Christer Stenby Ejsing; Douglas G Burrin; Kerstin Skovgaard; Vibeke Brix Christensen; Thomas Thymann; Stanislava Pankratova Journal: Physiol Rep Date: 2022-07
Authors: Sara Straniero; Amit Laskar; Christina Savva; Jennifer Härdfeldt; Bo Angelin; Mats Rudling Journal: J Lipid Res Date: 2020-02-21 Impact factor: 5.922
Authors: Emil Bluhme; Ewa Henckel; Roberto Gramignoli; Therese Kjellin; Christina Hammarstedt; Greg Nowak; Ahmad Karadagi; Helene Johansson; Öystein Jynge; Maria Söderström; Björn Fischler; Stephen Strom; Ewa Ellis; Boubou Hallberg; Carl Jorns Journal: Cell Transplant Date: 2022 Jan-Dec Impact factor: 4.064
Authors: Helene Johansson; Jonas Nørskov Søndergaard; Carl Jorns; Claudia Kutter; Ewa C S Ellis Journal: Front Endocrinol (Lausanne) Date: 2021-02-22 Impact factor: 5.555